NewAmsterdam Pharma (NASDAQ:NAMS) Announces Quarterly Earnings Results, Beats Estimates By $0.35 EPS

Key Points

• NewAmsterdam Pharma beat quarterly estimates: EPS was a loss of $0.14 versus the expected loss of $0.49, while revenue of $19.16 million topped the $7.54 million consensus.
• Analysts have a Moderate Buy consensus rating and an average price target of $48.90; ratings range from one Sell to nine Buys among 12 analysts.
• The stock rose $0.81 to $20.71 in Wednesday’s mid-day trading, though it remained below its 50-day and 200-day moving averages.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.35, FiscalAI reports. NewAmsterdam Pharma had a negative return on equity of 34.81% and a negative net margin of 3,644.21%. The firm had revenue of $19.16 million for the quarter, compared to analyst estimates of $7.54 million.

NewAmsterdam Pharma Price Performance

NASDAQ:NAMS traded up $0.81 during mid-day trading on Wednesday, reaching $20.71. The stock had a trading volume of 1,473,854 shares, compared to its average volume of 1,171,273. The business's 50 day moving average is $22.56 and its 200 day moving average is $29.71. NewAmsterdam Pharma has a fifty-two week low of $19.13 and a fifty-two week high of $42.21. The stock has a market cap of $2.48 billion, a P/E ratio of -9.59 and a beta of 0.15.

Analysts Set New Price Targets

A number of research firms have recently issued reports on NAMS. HC Wainwright reissued a "buy" rating and issued a $52.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, September 8th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of NewAmsterdam Pharma in a research report on Thursday, October 15th. BMO Capital Markets began coverage on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. They issued an "outperform" rating and a $58.00 price objective on the stock. Jefferies Financial Group reiterated a "buy" rating and issued a $45.00 target price on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. Finally, Royal Bank Of Canada decreased their target price on shares of NewAmsterdam Pharma from $50.00 to $42.00 and set an "outperform" rating for the company in a research note on Monday, October 5th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $48.90.

Insider Activity at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CEO Michael H. Davidson purchased 10,000 shares of the company's stock in a transaction dated Monday, September 14th. The shares were bought at an average price of $22.65 per share, for a total transaction of $226,500.00. Following the purchase, the chief executive officer directly owned 792,923 shares in the company, valued at $17,959,705.95. This trade represents a 1.28% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director John W. Smither sold 1,600 shares of the firm's stock in a transaction on Friday, September 4th. The shares were sold at an average price of $25.32, for a total transaction of $40,512.00. Following the transaction, the director owned 8,760 shares in the company, valued at $221,803.20. This represents a 15.44% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 176,846 shares of company stock valued at $4,661,919. 12.74% of the stock is currently owned by corporate insiders.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma NASDAQ: NAMS is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases. The company's primary investigational product is obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor designed to reduce low-density lipoprotein cholesterol and potentially address residual cardiovascular risk in patients who remain inadequately controlled on existing treatments.

NewAmsterdam is evaluating obicetrapib in late-stage clinical studies involving patients with dyslipidemia, including individuals with heterozygous familial hypercholesterolemia and patients who are unable to reach cholesterol goals with currently available therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.